The momentum of funding in biopharmaceutical continues, as organizations focus on advancing R&D for respective leading therapy and treatment candidates undergoing clinical testing. Companies such as Veradermics Inc., Peptilogics, and BridGene Biosciences all recently announced the completion of major funding rounds, helping to advance clinical testing.

Veradermic Incorporated

Veradermics announced the completion of an oversubscribed $150 million Series C financing round.¹ The funding is expected to support the registrational development and planned New Drug Application submission for Veradermics’ lead investigational product, VDPHL01, which holds potential to be the first and only extended-release oral minoxidil treatment designed specifically for hair regrowth in women and men.¹ According to a press release from Veradermic, the collected capital will be invested in advancing and completing the ongoing Phase III trials for its lead candidate.

SR One led the financing round and received a mixed participation from both new and current investors, including the following.

• Viking Global Investors
• Marshall Wace
• Invus
• Funds managed by abrdn Inc.
• Columbia Threadneedle Investments
• Infinitium
• LifeSci Venture Partners
• Longitude Capital
• Suvretta Capital Management
• Surveyor Capital
• Other undisclosed investors

“As a dermatologist, I’ve seen firsthand the emotional toll of pattern hair loss and watched as patients have had to settle for inconvenient, poorly tolerated, or off-label, non-clinically validated treatments,” said Reid Waldman, M.D., chief executive officer of Veradermics. “We built Veradermics to change that. With VDPHL01, we’ve engineered an extended-release oral formulation of minoxidil that we believe can maximize hair growth potential while minimizing cardiac risks to safely regrow hair. We’re thrilled to see early indications of this playing out in the clinic, with preliminary Phase II data in males on VDPHL01 that indicate visible, measurable regrowth as early as two months. Backed by a strong syndicate in this financing, including current and new investors, we aim to deliver on the potential promise of VDPHL01 and bring a new prescription option forward that could meaningfully impact the lives of millions of women and men with this potentially distressing condition.”

Peptilogics

Peptilogics announced the completion of an oversubscribed $78 million Series B2 financing round, with the funds planned to support the company's Phase II/III pivotal trial of zaloganan (PLG0206), which is an investigational treatment for prosthetic joint infections (PJI).² Accorind to a news release from Peptilogics,the financing round was led by Presight Capital, Thiel Bio, and Founders Fund, and included contributions from new investors such as AMR Action Fund, Narya Capital, and Beyond Ventures.² Following the financing round, Peptilogics' total equity funding increased to around $120 million, and gained substantial grant support from CARB-X.

"What these investors understood is that hardware-related infections like PJI are different from other common infections. We chose to focus on this huge unmet need because the lack of effective therapeutic options alters the commercial landscape that has made antibiotic development difficult," said Peptilogics' CEO Jonathan Steckbeck, PhD. "Developing treatments for these infections allows us to create a new category of surgical therapeutics for patients who currently have to undergo multiple life-changing surgeries to eliminate the infection."

BridGene Biosciences

BridGene Biosciences revealed its conclusion of a $28 million Series B+ financing round, led by Bayland Capital. The financing round included contributions from GTJA Investment Group, Proxima Ventures, and existing investors Lapam Capital and Grains Valley Venture Capital. Funds from the round are expected to advance BridGene’s BGC-515, a covalent TEAD inhibitor for solid tumors, through ongoing clinical development and toward Phase II. Additionally, the round is expected to finance the company’s second program, which has potential to enter the clinic in 2027, and accelerate the development of additional programs in oncology and autoimmune diseases.³ The financing round is also expected to boost BridGene's capacity to expand strategic collaborations, and also further validate the broad applicability of its IMTAC chemoproteomic platform across oncology, immunology, and neurology.³

"Our recent financing provides important resources to advance our lead program, BGC-515, a covalent TEAD inhibitor, through Phase 2 clinical development," said Ping Cao, Ph.D., CEO and co-founder of BridGene Biosciences. "This funding will also enable us to progress additional pipeline programs toward the clinic and further expand the reach of our IMTAC™ chemoproteomic platform through strategic collaborations, as we continue to translate our discoveries into transformative therapies for patients."

Sources

1. Veradermics Announces Oversubscribed $150 Million Series C Financing to Advance VDPHL01 Through Multiple Phase 3 Trials as Potentially the First Non-Hormonal Oral Therapeutic for Hair Regrowth in Women and Men Veradermics October 16, 2025 https://www.businesswire.com/news/home/20251016863981/en/Veradermics-Announces-Oversubscribed-%24150-Million-Series-C-Financing-to-Advance-VDPHL01-Through-Multiple-Phase-3-Trials-as-Potentially-the-First-Non-Hormonal-Oral-Therapeutic-for-Hair-Regrowth-in-
2. Peptilogics Raises $78 Million to Advance Zaloganan Into Pivotal Trial Peptilogics Otober 16, 2025 https://www.prnewswire.com/news-releases/peptilogics-raises-78-million-to-advance-zaloganan-into-pivotal-trial-302585651.html
3. BridGene Biosciences Raises $28 Million in Series B+ Financing to Accelerate Clinical Development of BGC-515 and Platform Expansion BrigGene Biosciences October 16, 2025 https://www.prnewswire.com/news-releases/bridgene-biosciences-raises-28-million-in-series-b-financing-to-accelerate-clinical-development-of-bgc-515-and-platform-expansion-302585734.html